Based on publicly available data as of June 30, 2026, the most defensible estimated net worth for Sir Mene Pangalos sits in the range of $4 million to $8 million. The lower bound aligns with aggregator estimates like PeopleAi's $4.35 million figure, while the upper end accounts for accumulated career compensation, board equity, and investment activity that public filings hint at but do not fully disclose. This is not a precise accounting number. It is a research-based range built from verifiable income streams, SEC proxy disclosures, and reasonable assumptions about savings and assets for a career-level pharmaceutical executive.
Mene Pangalos Net Worth: Estimate, Sources, and Meaning
Marcus Thorne
30 Jun 2026
Who Mene Pangalos is and why net worth estimates vary
Sir Menelas (Mene) Pangalos is a British neuroscientist and pharmaceutical R&D executive with a career spanning some of the biggest names in the industry. European Pharmaceutical Review’s profile of Mene Pangalos highlights his R&D leadership and public-facing industry recognitions, which helps contextualize how his public roles relate to estimating income and net worth R&D executive with a career spanning some of the biggest names in the industry.
He has held senior roles at SmithKline Beecham, Janssen Pharmaceutica, Bristol-Myers Squibb, Wyeth (VP of Neuroscience Research, 2003 to 2008), and GlaxoSmithKline (Group Director and Head of Neurodegenerative Research). Most prominently, he served as Executive Vice President of Biopharmaceuticals R&D at AstraZeneca starting in January 2019, overseeing the creation of AstraZeneca's global R&D centre in Cambridge before retiring from the company in April 2024.
He is a Fellow of the Royal Society (FRS), holds a knighthood, and currently sits on the boards of Biogen and Absci. He is not a musician, content creator, or entertainment personality, which makes him an unusual subject for celebrity net-worth coverage. But his senior executive profile, public company board roles, and SEC-disclosed compensation make him a legitimate subject for a research-driven wealth estimate.
Net worth estimates for someone like Pangalos vary widely for a few reasons. First, most of his career compensation has been private, meaning salaries and bonuses from pharma giants like AstraZeneca, Wyeth, and GlaxoSmithKline were never publicly disclosed in the same way a public company CEO's pay is. Second, his wealth sits largely in professional savings, deferred compensation, and equity, none of which appears in a single public document. Third, aggregator sites use different methodologies, some social-signal based, some SEC-scraping based, and they rarely agree. The result is a wide spread of estimates with very different foundations.
What "net worth" actually means here
Net worth is assets minus liabilities, full stop. If you are comparing this approach to a more hype-driven page like stock lizard king net worth, the key difference is that the net-worth number there usually reflects assumptions rather than a clean assets-minus-liabilities tally. For a pharmaceutical executive, assets typically include cash and savings, investment portfolios, real estate, vested equity in public companies, and any business ownership stakes. Liabilities include mortgages, loans, and any outstanding obligations. The number you see on aggregator sites is almost never a real assets-minus-liabilities calculation. It is usually a backward inference from estimated career earnings, adjusted by assumptions about lifestyle spending, taxes, and investment returns.
One concept that trips people up is equity compensation. Pangalos holds options to purchase 140,214 shares and 3,675 RSUs in Absci, according to SEC filings. At first glance that sounds like significant wealth. But as the Biogen DEF 14A filed in April 2026 makes clear, some of those options are underwater, meaning the exercise price is above the current market price, so they carry $0 in realized value at that snapshot date. Unvested RSUs also do not count until they vest. Treating the full face value of equity grants as current wealth is one of the most common errors in these estimates.
Where to actually look for reliable data
For someone with Pangalos's profile, the most trustworthy data comes from SEC filings, not celebrity net-worth aggregators. Here is the practical research workflow.
- SEC EDGAR DEF 14A filings: Biogen's proxy statement (filed April 28, 2026) is the most detailed public record. It includes a director compensation table listing Pangalos with $140,000 in cash fees, $299,947 in stock awards, and a total of $439,947 for the relevant fiscal period. Search SEC EDGAR for Biogen's DEF 14A to get the primary source.
- Absci's proxy and SEC filings: Absci's 2025 proxy documents Pangalos's equity holdings, including 106,200 options granted in January 2024 and additional tranches, plus RSUs. Hargreaves Lansdown's director dealings tracker also shows a May 2026 transaction for Absci shares under his name, which helps validate equity activity.
- PeopleAi and similar aggregators: PeopleAi's May 2026 estimate of $4.35 million is a useful reference point, but their own disclaimer notes it is based on 'a combination of social factors' and is not guaranteed accurate. Use it as a floor, not a fact.
- Insidertrades.com and Insider Drift: These platforms pull SEC-sourced insider transaction data and are useful for tracking when Pangalos buys or sells equity, which gives clues about liquidity and wealth realization.
- Salary.com: Their Absci board member compensation profile for Pangalos lists approximately $470,254 in total compensation. Cross-check this against Absci's SEC proxy to verify, since aggregators sometimes mix cash and equity values inaccurately.
- Royal Society and Clare Hall Cambridge biographies: These confirm career scope and seniority, which are inputs to any compensation plausibility check.
Breaking down Mene Pangalos's income streams
Pangalos's wealth comes from multiple career phases, each contributing differently to his current net worth.
Executive salary and bonuses (career phase, now concluded)
From 2003 through April 2024, Pangalos held VP and EVP-level roles at Wyeth, GlaxoSmithKline, and AstraZeneca. Executive compensation at that level in global pharma typically ranges from $500,000 to over $2 million annually when salary, annual bonuses, and long-term incentives are combined. Over a 20-plus year career at that tier, cumulative pre-tax earnings in the range of $15 million to $30 million is plausible, though taxes, lifestyle costs, and market timing on equity sales all reduce the amount that translates into current net worth.
Board of directors compensation (current, ongoing)
Since retiring from AstraZeneca in April 2024, Pangalos has transitioned into a board service model. The Biogen DEF 14A for 2025 is the clearest public data point: $140,000 in cash fees and roughly $300,000 in stock awards for a total of around $440,000 annually from Biogen alone. His Absci board role adds further cash and equity, with Salary.com citing approximately $470,000 in total Absci board compensation. Combined, his current board compensation likely runs between $700,000 and $1 million annually before taxes, with a significant portion in equity that may or may not be realizable depending on vesting and market conditions.
Equity holdings and investment activity
Pangalos holds options and RSUs in both Biogen and Absci. Absci's SEC filings document 140,214 options and 3,675 RSUs, with some tranches granted in January 2024 and June 2024. The key caveat: as noted in Biogen's own proxy filing, some options are underwater and carry $0 in realized value at a given snapshot date. His actual wealth from equity depends heavily on stock prices at the time of exercise or vesting. He also joined Omega Funds in an advisory capacity, per BioPharma Dive, which may represent carried interest or advisory compensation that is difficult to quantify publicly.
Publications and speaking (minor contribution)
Pangalos has contributed to scientific publications, including editorial roles in translational neuroscience texts. Scientific authorship royalties are generally very modest and unlikely to move the needle on a net worth estimate. Speaking fees at pharma and biotech conferences, however, can run $10,000 to $50,000 per engagement for executives of his profile, though the frequency is not publicly documented.
Estimated net worth ranges and how they are calculated
| Estimate Source | Figure | Methodology | Confidence Level |
|---|---|---|---|
| PeopleAi (May 2026) | $4.35 million | Social signal aggregation, not assets-minus-liabilities | Low (acknowledged by source as non-guaranteed) |
| Conservative assets-based model | $4 million to $6 million | Accumulated career savings (heavy tax/lifestyle discount), current vested equity, modest real estate assumption | Moderate |
| Mid-range research estimate | $6 million to $8 million | Career earnings model plus board equity at current market value, advisory income assumptions | Moderate |
| Upper-bound estimate | $8 million to $12 million | Includes favorable assumptions on AstraZeneca equity realization, multiple property ownership, and investment portfolio growth | Low to Moderate |
The most defensible single range, given publicly available evidence, is $4 million to $8 million. The $4.35 million PeopleAi figure aligns with the conservative end. The upper range of $8 million assumes favorable equity realizations and investment portfolio growth but is not supported by specific public documents. Any estimate above $10 million would require assumptions that go well beyond what the data supports. If you are also looking up unrelated profiles like alobo naga net worth, use the same rule: rely on filings and primary evidence rather than a single aggregator number.
How to verify or update this estimate yourself
This estimate was assembled using publicly available data as of June 30, 2026. The primary sources are Biogen's DEF 14A proxy (filed April 28, 2026) and Absci's 2025 SEC proxy. Both are searchable on SEC EDGAR using the company names and filing type 'DEF 14A.' The Absci equity transaction logged on Hargreaves Lansdown in May 2026 is also a useful cross-reference for recent equity activity.
To update this estimate, check these steps in order. First, pull the most recent DEF 14A filings from Biogen and Absci on SEC EDGAR to get updated director compensation tables. Second, look up Absci and Biogen current stock prices to calculate the current market value of Pangalos's vested equity. Third, check Insider Drift or similar SEC-sourced platforms for any recent share transactions that suggest equity was sold or new grants were made.
Fourth, compare the total to the PeopleAi figure as a rough sanity check. If you are looking specifically for the royal and the serpent net worth claim, treat it as another aggregator-style estimate unless it is backed by SEC filings and clearly documented equity realizations.
If the SEC-derived number is far above or below $4 million to $8 million, look for a specific event (a large block of vested equity, a company acquisition, or an announced severance) that could explain the gap.
Common misconceptions about figures like this one
- Salary equals net worth: A pharmaceutical EVP earning $1.5 million a year does not have $1.5 million in net worth. After taxes, living expenses, mortgage payments, and investment allocation, the amount that accumulates over time is substantially lower. Annual income is an input to net worth, not a synonym for it.
- Equity grants are instant wealth: Pangalos's SEC-disclosed options and RSUs are not cash in a bank account. Some are underwater, some are unvested, and even vested equity must be sold at market price to realize its value. A grant of 140,000 options at a strike price above the current market price is worth exactly $0 today.
- Aggregator numbers are calculated: Sites like PeopleAi and Insidertrades.com use formulas based on social signals, SEC data snippets, or industry salary benchmarks. They do not conduct an actual assets-minus-liabilities analysis, and their own disclaimers acknowledge this.
- One number is the right number: Net worth is a snapshot, not a fixed fact. Pangalos's net worth in April 2024 (when he was still at AstraZeneca) was almost certainly different from his net worth in June 2026 (post-retirement, living on board fees and equity). Estimates age quickly.
- A knighthood or FRS fellowship signals extreme wealth: These are honors recognizing scientific contribution, not financial status. Many knights and fellows of the Royal Society have very modest personal finances relative to what the titles imply.
Mene Pangalos is an unusual subject for this type of coverage compared to, say, content creators or entertainers whose income is tracked through brand deals and streaming royalties. His wealth story is quieter and more institutional: decades of senior pharma salaries, accumulated equity, and a post-retirement board portfolio that currently generates close to $1 million annually in cash and stock. The numbers are real, they are just spread across documents that take a bit of digging to find. The $4 million to $8 million range reflects what those documents actually support. If you also ran into claims about exotics lair net worth, treat them the same way: look for primary, documentable evidence rather than relying on aggregator numbers.
FAQ
Why do SEC director compensation numbers not always match the “net worth” totals people quote?
Not necessarily. In most SEC proxies, director compensation tables usually include cash fees and the value of stock awards at grant-date (or a specified accounting value), while the realized value depends on vesting timing and later stock prices. To estimate what is truly “in wealth” today, you need to separate vested and exercisable equity from unvested RSUs, and exclude options that are currently underwater.
How should I treat options and RSUs when estimating Mene Pangalos net worth?
The main pitfall is counting grant-face value as if it were current cash. For options, you only gain value if the current market price is above the option exercise price (and after any taxes and fees). For RSUs, value only appears when they vest. The article notes an example of underwater options, which is exactly why many aggregator calculations can overshoot.
What is the correct method if I want a more precise assets-minus-liabilities estimate?
Use current market valuation only for equity that is vested or exercisable (and for options that are in the money), then subtract any documented loans or other liabilities you can verify. If you can’t verify liabilities, you can’t reliably compute a true “assets minus liabilities” number, so stick to a range and be explicit about what’s assumed versus what’s sourced.
Why can yearly board compensation changes make net worth estimates look inconsistent?
Because director fees and stock awards can fluctuate by year, and because a single proxy typically covers only the reporting period. If someone’s board roles changed (new board, committee changes, retirement from a board), the compensation profile can jump. When updating the estimate, compare the latest two proxy years to see whether the annual baseline is trending up or down.
What would explain a net worth estimate that is much higher or much lower than $4 million to $8 million?
If you see an estimate far above the $4 million to $8 million range, the likely cause is treating unvested equity or underwater options as if they are already realizable, or assuming very large investment gains without any underlying evidence. Conversely, a low figure usually means missing board stock awards, advisory compensation, or undercounting vested equity realizations.
Why can’t we just use “salary plus bonuses” to compute net worth for this kind of executive?
Not by itself. Public disclosures rarely provide a full snapshot of personal assets like investment account balances or real estate holdings, so net worth estimates depend on compensation history and equity realizations. If you want higher confidence, you need a reconciliation step: track equity grants, vesting, any reported sales, and then infer what remains likely saved versus spent.
How can insider share sale or exercise activity help refine the net worth range?
Check for share transactions that indicate liquidity events, for example exercises that turn options into shares and then sales, or direct sales reported by insiders. The practical step in the article suggests using SEC-sourced tools to look for recent insider activity, but the key caveat is timing, because sales can occur for tax and diversification reasons that do not necessarily increase net worth at a later date.
Do different types of board and advisory compensation affect the net worth calculation differently?
Yes, because not all “board income” is the same. Some stock awards vest quickly, others vest over years; some advisory roles are cash-only, others include equity-like economics; and committee roles can change the cash fees. For a better estimate, break compensation into cash, vested equity, and potentially realizable equity, rather than lumping everything into one figure.
What’s the best order of operations when updating the net worth estimate with new filings?
If you are doing your own update, don’t rely on only one filing date. A DEF 14A describes compensation for a prior period, while stock prices move daily and vesting schedules span multiple dates. The article’s workflow implies a sequence, and the missing decision aid is to recompute equity value using the current trading price only for the portion that is already vested or exercisable.
Should I treat PeopleAi or similar aggregator numbers as confirmation or as a red flag?
Be careful with aggregator “sanity checks.” If an aggregator’s number is close to the SEC-supported range, it might be using reasonable assumptions, but it still may be overstating realizable equity. If it diverges a lot, treat it as a warning sign and look for which components are likely mis-modeled, such as underwater options, unvested RSUs, or unrealized valuation assumptions.
Next Article
Lion and Loki Net Worth: Estimates, Sources, and How to Verify
Lion vs Loki net worth estimates with verified sources, income breakdowns, and steps to check updates reliably.
